Tagged with Therapy

Pharma Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Now part of the Sanofi group, as SanofiGenzyme, it benefits from the reach and resources of one of the world’s largest pharmaceutical companies with a shared commitment to improving the lives of patients. The general manager…

Pharma The general manager of Bard SA, Charl De Klerk, illustrates the company’s growth ambitions within South Africa and Sub-Saharan Africa, while also depicting how Bard has adapted its therapeutic portfolio to the dynamics of South Africa and the type of pipeline innovations that will strengthen its competitive positioning in the…

Pharma Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory environment and market access. We are becoming, both at national and global levels, a company that supplies highly evidence-based medicines,…

Pharma Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented neo-epitopes combination, its plans to break into the immuno-oncology domain and its perspectives on the French regulatory and biotech environments, and emphasizes…

Pharma The CSO and COO of BioNovion talk about the company’s recent acquisition by US-based biotech Aduro. BioNovion is a Dutch biopharma specialized in immune oncology antibody discovery. Immunotherapy has become a clinical reality as an effective approach to treat advanced cancer and BioNovion plans to keep leveraging the fruitful collaboration with top-notch research centers…

Pharma Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than the symptoms of this disease and the current research climate in the Netherlands. Introduction to Bart Roep and his current…

Holland Pharming Group CEO Sijmen de Vries discusses the advantages of his company’s transgenic platform for recombinant protein production, the commercial progress of their lead product Ruconest, and the company’s plans for developing new applications through the platform, including a partnership with the SinoPharm subsidiary SIPI. From a production point of…